Acta Scientific Microbiology (ISSN: 2581-3226)

Review ArticleVolume 4 Issue 6

The CRISPR-Cas System as a Technology to Redefine Industrial Biotechnology

Anirban Goutam Mukherjee1, Uddesh Ramesh Wanjari2*, Sampada Prakash Pendse3, Akruti Amol Ingole4, Piyush Jagdish Balgote5 and Surbhi Balwant Dhoke2

1Department of Biotechnology, School of Bio-Sciences and Technology, Vellore Institute of Technology, Vellore, Tamil Nadu, India
2Department of Biochemistry, Kamla Nehru Mahavidyalaya, Nagpur, Maharashtra, India
3Department of Biochemistry, RTM Nagpur University, Nagpur, Maharashtra, India
4Department of Biotechnology, Priyadarshini Institute of Engineering and Technology, Nagpur, Maharashtra, India
5Molecular Biology and Genetic Engineering, RTM Nagpur University, Nagpur, Maharashtra, India

*Corresponding Author: Uddesh Ramesh Wanjari, Department of Biochemistry, Kamla Nehru Mahavidyalaya, Nagpur, Maharashtra, India.

Received: April 24, 2021; Published: May 17, 2021

Citation: Uddesh Ramesh Wanjari., et al. “The CRISPR-Cas System as a Technology to Redefine Industrial Biotechnology”. Acta Scientific Microbiology 4.6 (2021): 45-52.

  CRISPR technology has revolutionized the field of Industrial Biotechnology, producing numerous miracles. Several CRISPR/Cas9-based methodologies help simple, quick strain development in yeast and investigate their potential for the synchronous presentation of different hereditary alterations, thus promoting and increasing the efficacy of several industrial technologies. CRISPR/Cas9 framework aimed at fast genome altering of Clostridium ljungdahlii is a known wide target intended for business creation and increasing ethanol's productivity from union gas by several folds. CRISPR-Cas frameworks have prospective for numerous microbes designing solicitations and bacterial strain composing inoculation of societies, self-immunity or auto-focused on cells execution, plus the designing or regulator of metabolic paths enhanced biochemical combination. CRISPR-related protein 9 (Cas9), by the RNA-guided endonuclease specifically, stood out for its guarantee in fundamental examination and quality altering built therapeutics. This review focuses on various industrial and pharmaceutical Biotechnology advancements, including the top qualities for CRISPR-Cas frameworks featuring how these highlights can be utilized in the modern scenario.

Keywords: CRISPR; Industrial Biotechnology; RNA-guided; Yeast; Bacteriophages

Bibliography

  1. Nielsen AA and Voigt CA. “Multi‐input CRISPR/C as genetic circuits that interface host regulatory networks”. Molecular Systems Biology 10 (2014): 763.
  2. van Hijum SA., et al. “Application of state-of-art sequencing technologies to indigenous food fermentations”. Current Opinion in Biotechnology 24 (2013): 178-186.
  3. Logares R., et al. “Environmental microbiology through the lens of high-throughput DNA sequencing: Synopsis of current platforms and bioinformatics approaches”. Journal of Microbiological Methods 91 (2012): 106-113.
  4. Villadsen K. “'Polyphonic' welfare: Luhmann's systems theory applied to modern social work: Polyphonic social work”. International Journal of Social Welfare 17 (2008): 65-73.
  5. Katz L., et al. “Synthetic biology advances and applications in the biotechnology industry: a perspective”. Journal of Industrial Microbiology and Biotechnology 45 (2018): 449-461.
  6. Mans R., et al. “CRISPR/Cas9: a molecular Swiss army knife for simultaneous introduction of multiple genetic modifications in Saccharomyces cerevisiae”. FEMS Yeast Research 15 (2015).
  7. Anirban Goutam Mukherjee and Uddesh Ramesh Wanjari. “A Review on the Present and Future Aspects of Various Prokaryotic Pigments and Metabolites Demonstrating Anti-Cancerous Properties”. IJERT V9, IJERTV9IS070578 (2020).
  8. Mukherjee AG., et al. “A review on the usefulness of various eukaryotic pigments and metabolites in cancer treatment”. WJPR 9 (2020): 26.
  9. Batianis C., et al. “An expanded CRISPRi toolbox for tunable control of gene expression in Pseudomonas putida”. Microbial Biotechnology 13 (2020): 368-385.
  10. Nødvig CS., et al. “A CRISPR-Cas9 System for Genetic Engineering of Filamentous Fungi”. PLoS ONE 10 (2015): e0133085.
  11. Zhang S., et al. “Recent Advances of CRISPR/Cas9-Based Genetic Engineering and Transcriptional Regulation in Industrial Biology”. Frontiers in Bioengineering and Biotechnology 7 (2020): 459.
  12. Ramesh A., et al. “Guide RNA Engineering Enables Dual Purpose CRISPR-Cpf1 for Simultaneous Gene Editing and Gene Regulation in Yarrowia lipolytica”. ACS Synthetic Biology 9 (2020): 967-971.
  13. Borges AL., et al. “Bacteriophage Cooperation Suppresses CRISPR-Cas3 and Cas9 Immunity”. Cell 174 (2018): 917-925.e10.
  14. Ma Y., et al. “Increasing the efficiency of CRISPR/Cas9-mediated precise genome editing in rats by inhibiting NHEJ and using Cas9 protein”. RNA Biology 13 (2016): 605-612.
  15. Marcó MB., et al. “Bacteriophages and dairy fermentations”. Bacteriophage 2 (2012): 149-158.
  16. Donohoue PD., et al. “Advances in Industrial Biotechnology Using CRISPR-Cas Systems”. Trends in Biotechnology 36 (2018): 134-146.
  17. Patel VK., et al. “CRISPR-Cas9 System for Genome Engineering of Photosynthetic Microalgae”. Molecular Biotechnology 61 (2019): 541-561.
  18. Peters JM., et al. “Enabling genetic analysis of diverse bacteria with Mobile-CRISPRi”. Nature Microbiology 4 (2019): 244-250.
  19. Larson MH., et al. “CRISPR interference (CRISPRi) for sequence-specific control of gene expression”. Nature Protocol 8 (2013): 2180-2196.
  20. Wang Q and Wang L. “New Methods Enabling Efficient Incorporation of Unnatural Amino Acids in Yeast”. Journal of the American Chemic al Society130 (2008): 6066-6067.
  21. Beekwilder J., et al. “Polycistronic expression of a β-carotene biosynthetic pathway in Saccharomyces cerevisiae coupled to β-ionone production”. Journal of Biotechnology 192 (2014): 383-392.
  22. Wieczorke R., et al. “Concurrent knock-out of at least 20 transporter genes is required to block uptake of hexoses in Saccharomyces cerevisiae”. FEBS Letters 464 (1999): 123-128.
  23. Srivastava N., et al. “Applications of fungal cellulases in biofuel production: Advances and limitations”. Renewable and Sustainable Energy Reviews 82 (2018): 2379-2386.
  24. Ruiz-Diez B. “Strategies for the transformation of filamentous fungi”. Journal of Applied Microbiology 92 (2002): 189-195.
  25. Meyer V., et al. “Genetics, Genetic Manipulation, and Approaches to Strain Improvement of Filamentous Fungi”. in: Baltz, R.H., Davies, J.E., Demain, A.L., Bull, A.T., Junker, B., Katz, L., Lynd, L.R., Masurekar, P., Reeves, C.D., Zhao, H. (Eds.), Manual of Industrial Microbiology and Biotechnology. ASM Press, Washington, DC, USA (2014): 318-329.
  26. Stein HP., et al. “Potential for CRISPR Genetic Engineering to Increase Xenobiotic Degradation Capacities in Model Fungi”. in: Prasad, R., Aranda, E. (Eds.), Approaches in Bioremediation, Nanotechnology in the Life Sciences. Springer International Publishing, Cham (2018): 61-78.
  27. Horvath P., et al. “Applications of the Versatile CRISPR-Cas Systems”. in: Barrangou, R., van der Oost, J. (Eds.), CRISPR-Cas Systems. Springer Berlin Heidelberg, Berlin, Heidelberg (2013): 267-286.
  28. Arentshorst M., et al. “Using Non-homologous End-Joining-Deficient Strains for Functional Gene Analyses in Filamentous Fungi”. in: Bolton, M.D., Thomma, BPHJ (Eds.), Plant Fungal Pathogens, Methods in Molecular Biology. Humana Press, Totowa, NJ (2012): 133-150.
  29. Sharma S., et al. “Trichoderma: Biodiversity, Ecological Significances, and Industrial Applications”. in: Yadav, A.N., Mishra, S., Singh, S., Gupta, A. (Eds.), Recent Advancement in White Biotechnology Through Fungi, Fungal Biology. Springer International Publishing, Cham (2019): 85-120.
  30. Zhao Y., et al. “CRISPR/dCas9-Mediated Multiplex Gene Repression in Streptomyces”. Biotechnology Journal 13 (2018): 1800121.
  31. Nielsen ML., et al. “Genes Linked to Production of Secondary Metabolites in Talaromyces atroroseus Revealed Using CRISPR-Cas9”. PLoS ONE 12 (2017): e0169712.
  32. Huang H., et al. “CRISPR/Cas9-Based Efficient Genome Editing in Clostridium ljungdahlii , an Autotrophic Gas-Fermenting Bacterium”. ACS Synthetic Biology 5 (2016): 1355-1361.
  33. Leang C., et al. “A Genetic System for Clostridium ljungdahlii: a Chassis for Autotrophic Production of Biocommodities and a Model Homoacetogen”. Applied and Environmental Microbiology 79 (2013): 1102-1109.
  34. Hawkins AS., et al. “Biological conversion of carbon dioxide and hydrogen into liquid fuels and industrial chemicals”. Current Opinion in Biotechnology 24 (2013): 376-384.
  35. Mock J., et al. “Energy Conservation Associated with Ethanol Formation from H 2 and CO 2 in Clostridium autoethanogenum Involving Electron Bifurcation”. Journal of Bacteriology 197 (2015): 2965-2980.
  36. Ueki T., et al. “Converting Carbon Dioxide to Butyrate with an Engineered Strain of Clostridium ljungdahlii”. mBio 5 (2014): e01636-1714.
  37. Copeland MF., et al. “Application of TALEs, CRISPR/Cas and sRNAs as trans-acting regulators in prokaryotes”. Current Opinion in Biotechnology 29 (2014): 46-54.
  38. Barrangou R. “CRISPR-Cas systems and RNA-guided interference: CRISPR-Cas systems and RNA-guided interference”. WIREs RNA 4 (2013): 267-278.
  39. Barrangou R., et al. “Genomic impact of CRISPR immunization against bacteriophages”. Biochemical Society Transactions 41 (2013): 1383-1391.
  40. Quiberoni A., et al. “Streptococcus thermophilus bacteriophages”. International Dairy Journal 20 (2010): 657-664.
  41. Fineran PC and Charpentier E. “Memory of viral infections by CRISPR-Cas adaptive immune systems: Acquisition of new information”. Virology 434 (2012): 202-209.
  42. Labrie SJ., et al. “Bacteriophage resistance mechanisms”. Nature Reviews Microbiology 8 (2010): 317-327.
  43. Barrangou R., et al. “CRISPR Provides Acquired Resistance Against Viruses in Prokaryotes”. Science 315 (2007): 1709-1712.
  44. Wiedenheft B., et al. “RNA-guided genetic silencing systems in bacteria and archaea”. Nature 482 (2012): 331-338.
  45. Lee JS., et al. “CRISPR/Cas9-mediated genome engineering of CHO cell factories: Application and perspectives”. Biotechnology Journal 10 (2015): 979-994.
  46. Lin Y., et al. “CRISPR/Cas9 systems have off-target activity with insertions or deletions between target DNA and guide RNA sequences”. Nucleic Acids Research 42 (2014): 7473-7485.
  47. Anders C., et al. “Structural Plasticity of PAM Recognition by Engineered Variants of the RNA-Guided Endonuclease Cas9”. Molecular Cell 61 (2016): 895-902.
  48. Kleinstiver BP., et al. “Engineered CRISPR-Cas9 nucleases with altered PAM specificities”. Nature 523 (2015): 481-485.
  49. Harrington LB., et al. “A thermostable Cas9 with increased lifetime in human plasma”. Nature Communication 8 (2017): 1424.

Copyright: © 2021 Uddesh Ramesh Wanjari., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.



News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2021.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US